公开(公告)号：US20220370611A1

公开(公告)日：2022-11-24

申请号：US17529450

申请日：2021-11-18

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  In-Cheol SUN ,  Man Kyu SHIM ,  Ji Woong CHOI

IPC: A61K41/00 ,  A61P35/00 ,  A61K31/351 ,  A61K47/69

Abstract: Disclosed are visible light-activatable antitumor self-assembled nanoparticles or antitumor immunity-inducing self-assembled nanoparticles. The self-assembled nanoparticles induce potent apoptosis in cancer cells and increase their own anticancer immunogenicity, thereby maximizing their therapeutic efficacy for cancer.

公开(公告)号：US20230173083A1

公开(公告)日：2023-06-08

申请号：US17735371

申请日：2022-05-03

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  Hong Yeol YOON ,  In-Cheol SUN ,  Man Kyu SHIM ,  Hanhee CHO

IPC: A61K47/64 ,  A61K47/65 ,  A61K31/704 ,  A61P35/00

CPC classification number: A61K47/643 ,  A61K31/704 ,  A61K47/65 ,  A61P35/00

Abstract: Disclosed is a prodrug for preventing or treating cancer. The prodrug is mediated by albumin present in the blood to achieve high cancer selectivity for cancer and high stability. Also disclosed is a pharmaceutical composition for preventing or treating cancer including the prodrug. The anticancer prodrug and the pharmaceutical composition form a conjugate with albumin even without using a carrier or delivery vector when injected in vivo. Therefore, the anticancer prodrug and the pharmaceutical composition are effective in preventing or treating cancer, have increased in vivo half-lives, and can accumulate in cancer with increased efficiency to significantly alleviate the side effects of the anticancer drug.

公开(公告)号：US20230293719A1

公开(公告)日：2023-09-21

申请号：US17859078

申请日：2022-07-07

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  In-Cheol SUN ,  Hong Yeol YOON ,  Man Kyu SHIM ,  Suah YANG

IPC: A61K47/69 ,  A61P35/00 ,  A61K47/64

CPC classification number: A61K47/6915 ,  A61K47/64 ,  A61P35/00

Abstract: Disclosed is an optimal peptide-liposome complex capable of multivalent crosslinking with PD-L1 on the cell surface to induce degradation of PD-L1. The peptide-liposome complex effectively blocks PD-L1, an immune checkpoint on the surface of cancer cells, and prevents the recycling of PD-L1 by intracellular metabolism to induce complete degradation of PD-L1 in cancer cells, achieving an increased therapeutic effect on cancer.

公开(公告)号：US20140147493A1

公开(公告)日：2014-05-29

申请号：US14071803

申请日：2013-11-05

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ick Chan KWON ,  Kwang Meyung KIM ,  Sun Hwa KIM ,  In-Cheol SUN ,  Jin Hee NA ,  Sangmin LEE ,  Ju Hee RYU

IPC: A61K48/00 ,  A61K9/127

CPC classification number: A61K9/127 ,  C12N15/88 ,  C12Q1/686 ,  C12Q2563/159 ,  C12Q2563/161

Abstract: Disclosed is an efficient carrier for gene delivery to cells based on PCR. The PCR-based gene delivery carrier includes: a shell composed of neutral liposomes; and template DNA and PCR components including polymerase, dNTPs and primers for amplification of the template DNA by PCR, within an inner space defined by the shell. The gene delivery carrier enhances the gene loading efficiency of neutral liposomes without cytotoxicity. Further disclosed is a method for preparing the gene delivery carrier.

Abstract translation: 公开了基于PCR的基因递送至细胞的有效载体。 基于PCR的基因递送载体包括：由中性脂质体组成的壳; 和模板DNA和PCR组分，包括聚合酶，dNTP和引物，用于通过PCR扩增模板DNA，在由壳定义的内部空间内。 基因递送载体增强了中性脂质体的基因负载效率，而没有细胞毒性。 进一步公开的是制备基因递送载体的方法。